Onco-hematology Molecular Testing Market Size to Reach USD 1.5 billion by 2031 with a 12.5% CAGR, Boosted by Next-Generation Blood Cancer Diagnostics| Exclusive Report by Transparency Market Research, Inc.
03. Oktober 2024 23:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research, Inc., Oct. 03, 2024 (GLOBE NEWSWIRE) -- According to a report published by Transparency Market Research, the global onco-hematology...
Precipio’s Lab Detects BCR-ABL1 Oncogene Co-Expression of p190 & p210 Isoforms in a CML Patient By Using HemeScreen® Technology
22. Mai 2023 11:00 ET
|
Precipio, Inc.
NEW HAVEN, Conn., May 22, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. leveraged its proprietary HemeScreen technology as part of the diagnostic process to monitor a...
Chronic Myeloid Leukemia Market to Exhibit Significant Growth as Leading Companies Such as Novartis, Ascentage Pharma, Terns Pharmaceuticals, Sanofi, and Others are Exploring the Domain | DelveInsight
23. März 2023 06:00 ET
|
DelveInsight Business Research LLP
New York, USA, March 23, 2023 (GLOBE NEWSWIRE) -- Chronic Myeloid Leukemia Market to Exhibit Significant Growth as Leading Companies Such as Novartis, Ascentage Pharma, Terns Pharmaceuticals,...
Global Chronic Myeloid Leukemia Pipeline Insight | Clinical Trials Evaluation Research Report 2022 by DelveInsight
23. Mai 2022 13:00 ET
|
DelveInsight Business Research LLP
Las Vegas, USA, May 23, 2022 (GLOBE NEWSWIRE) -- Global Chronic Myeloid Leukemia Pipeline Insight | Clinical Trials Evaluation Research Report 2022 by DelveInsight Chronic Myeloid Leukemia...
Global Chronic Myeloid Leukemia Treatment Market to Surpass US$ 10,864.9 Million by 2028, Says Coherent Market Insights (CMI)
08. April 2022 09:10 ET
|
CMI
SEATTLE, April 08, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global chronic myeloid leukemia treatment market is estimated to be valued at US$ 7,216.3 million in 2021, and...
First quantitative diagnostic test validated for Treatment-Free Remission for Eligible Patients with Ph+ CML-CP Treated with Tasigna® Cleared by Health Canada
13. November 2018 00:00 ET
|
MolecularMD
PORTLAND, Ore. and CAMBRIDGE, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- MolecularMD Corporation received regulatory approval from Health Canada for the MRDx® BCR-ABL Test, a quantitative diagnostic...